Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Tumor cells often reprogram their metabolism for rapid proliferation. The roles of long noncoding RNAs (lncRNAs) in metabolism remodeling and the underlying mechanisms remain elusive. Through screening, we found that the lncRNA Actin Gamma 1 Pseudogene (
AGPG
) is required for increased glycolysis activity and cell proliferation in esophageal squamous cell carcinoma (ESCC). Mechanistically,
AGPG
binds to and stabilizes 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3). By preventing APC/C-mediated ubiquitination,
AGPG
protects PFKFB3 from proteasomal degradation, leading to the accumulation of PFKFB3 in cancer cells, which subsequently activates glycolytic flux and promotes cell cycle progression.
AGPG
is also a transcriptional target of p53; loss or mutation of
TP53
triggers the marked upregulation of
AGPG
. Notably, inhibiting
AGPG
dramatically impaired tumor growth in patient-derived xenograft (PDX) models. Clinically,
AGPG
is highly expressed in many cancers, and high
AGPG
expression levels are correlated with poor prognosis, suggesting that
AGPG
is a potential biomarker and cancer therapeutic target.
PFKFB3 enhances glycolysis to promote cancer cell proliferation. Here, the authors identify a long noncoding RNA in esophageal squamous cell carcinoma,
AGPG
, which interacts with PFKFB3 and promotes its stability, leading to increased glycolysis and proliferation.